Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Judith L. Gulikers"'
Autor:
Judith L. Gulikers, MSc, G.D. Marijn Veerman, MD, PhD, Merel Jebbink, MD, PhD, Paul D. Kruithof, PharmD, Christi M.J. Steendam, MD, PhD, René J. Boosman, PhD, Ron H.J. Mathijssen, MD, PhD, Vivianne C.G. Tjan-Heijnen, MD, PhD, Johanna H.M. Driessen, PhD, Safiye Dursun, MD, Egbert F. Smit, MD, PhD, Anne-Marie C. Dingemans, MD, PhD, Robin M.J.M. van Geel, PharmD, PhD, Sander Croes, PharmD, PhD, Lizza E.L. Hendriks, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100656- (2024)
Introduction: Brain metastases (BM) are common in patients with advanced EGFR-mutated (EGFRm+) NSCLC. Despite good BM-related outcomes of osimertinib, several patients still experience intracranial progression. A possible explanation is pharmacologic
Externí odkaz:
https://doaj.org/article/b8cb56c1a21d4838abe7a2a929f0a009
Autor:
Leila S. Otten, Berber Piet, Michel M. van den Heuvel, Catia Marzolini, Robin M.J.M. van Geel, Judith L. Gulikers, David M. Burger, Jenneke Leentjens, Rob ter Heine
Publikováno v:
European Respiratory Review, Vol 31, Iss 164 (2022)
Background The risk for thromboembolisms in nonsmall cell lung cancer (NSCLC) patients is increased and often requires treatment or prophylaxis with direct oral anticoagulants (DOACs). Small-molecule inhibitors (SMIs) to treat NSCLC may cause relevan
Externí odkaz:
https://doaj.org/article/021ff43369ae431abd9f0b019aca1b8f
Autor:
Judith L. Gulikers, Ard J. van Veelen, Elishia M. J. Sinkiewicz, Yvo M. de Beer, Mariëlle Slikkerveer, Leo M. L. Stolk, Vivianne C. G. Tjan‐Heijnen, Lizza E. L. Hendriks, Sander Croes, Robin M. J. M. van Geel
Publikováno v:
Biomedical Chromatography. 37
A liquid chromatography–tandem mass spectrometry method was developed and validated to quantify the small-molecule inhibitors (SMIs) brigatinib, lorlatinib, pralsetinib and selpercatinib, which are used in patients with oncogenic-driven non-small c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::caef5b034fd9d78c2586b3df4ecbcf13
https://cris.maastrichtuniversity.nl/en/publications/af269269-57c0-45bf-8c7f-120860afe266
https://cris.maastrichtuniversity.nl/en/publications/af269269-57c0-45bf-8c7f-120860afe266
Autor:
Elisabeth J R Litjens, Judith L. Gulikers, Sander Croes, Maureen J.B. Aarts, Marco J.W. Schreurs, Robin M. J. M. van Geel
Publikováno v:
Melanoma Research, 31(6), 579-581. Lippincott Williams & Wilkins
Melanoma Research, 31(6), 579-581. LIPPINCOTT WILLIAMS & WILKINS
Melanoma Research, 31(6), 579-581. LIPPINCOTT WILLIAMS & WILKINS
The effect of intermittent hemodialysis (IHD) on nivolumab serum concentrations in patients with severe renal impairment is largely unknown. Here, we present a 79-year-old patient with metastatic melanoma and end-stage renal disease on IHD three time
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a06159e62e4f35d86ffc8ed331228be
https://pure.eur.nl/en/publications/3552e2b0-df10-4202-8f3f-6e683bd0ba19
https://pure.eur.nl/en/publications/3552e2b0-df10-4202-8f3f-6e683bd0ba19